Amarin Q2 2025 Earnings Preview
Earnings Announcement: Amarin (NASDAQ: AMRN) is set to release its Q2 earnings on July 30th, with an expected EPS of -$0.61 and revenue of $53.76M, reflecting a 20.3% year-over-year decline.
Performance History: The company has consistently beaten EPS estimates in the past two years and has a mixed record on revenue estimates, with recent revisions showing no upward changes for EPS and one upward revision for revenue.
Trade with 70% Backtested Accuracy
Analyst Views on AMRN
About AMRN
About the author
Amarin Advances VASCEPA with Over 25 Million Global Prescriptions and New Therapy Insights
- Global Prescription Volume: Amarin's VASCEPA®/VAZKEPA® has surpassed 25 million prescriptions worldwide, demonstrating its broad acceptance and efficacy in cardiovascular treatment, thereby solidifying the company's market leadership.
- Therapeutic Innovation: The emergence of new therapies is expected to expand the use of existing treatment options, including VASCEPA, helping to meet the needs of tens of millions of cardiovascular disease patients globally, thus enhancing patient access and treatment outcomes.
- Clinical Evidence Support: According to the 2018 REDUCE-IT study, VASCEPA demonstrated a 25% reduction in cardiovascular events when used in conjunction with statin therapy, providing robust clinical support for its application in cardiovascular risk management.
- Market Expansion Plans: Amarin has signed a long-term exclusive licensing agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries, further enhancing its influence in the European market and expected to drive future sales growth.
Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 9, 2025
Validea's Upgrade for AMRN: Validea's Price/Sales Investor model, based on Kenneth Fisher's strategy, upgraded Amarin Corporation PLC (AMRN) from 28% to 60% due to improved fundamentals and valuation, indicating growing interest in the stock.
Company Overview: Amarin Corporation is a pharmaceutical company focused on developing therapeutics for cardiovascular health, primarily through its lead product, Vascepa, which is used to reduce triglyceride levels in patients with severe hypertriglyceridemia.
Kenneth Fisher's Background: Kenneth Fisher, a prominent money manager and author, is known for popularizing the price/sales ratio as a stock evaluation tool and is the founder of Fisher Investments, located in a forest preserve to encourage independent thinking away from Wall Street.
Validea's Investment Research: Validea provides investment research based on the strategies of successful investors like Warren Buffett and Benjamin Graham, offering stock analysis and model portfolios aimed at long-term market outperformance.
